Patents
Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
Patent Number: 6969608This patent covers the use of a type of stem cell composition derived from tissues having sensory receptors such as olfactor epithelium. The patent contains 1 independent claims. The first covers a composition of neural stem cells and a carrier, the neural stem cells being isolated from tissue containing sensory receptors, expressing nestin, proliferate in absence of EGF, can differentiate...
Inventors: Miller, Freda (Montreal, CA); Gloster, Andrew (Saskatoon, CA)
Assignee: McGill University (Montreal, CA)
Date of First Priority Issue: Monday August 26th, 1996
Nitric oxide manipulation of muscle satellite cell activation
Patent Number: 6967102This patent sounds (from its title) like it covers use of nitric oxide for activation of muscle stem cells. Given the inventor described a role for nitric oxide in this context (Anderson JE A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell. 2000 May;11(5):1859-74 janders@ms.umanitoba.ca), one would anticipate the claims to...
Inventor: Anderson, Judy E. (Winnipeg, CA)
Assignee: University of Manitoba (Winnipeg, CA)
Date of First Priority Issue: Wednesday November 3rd, 1999
Pancreatic islet cell growth factors
Patent Number: 6967100This patent teaches how to generate islet-like cells from fetal progenitors by culturing in the presence of one of the bone morphogenic proteins together with laminin or a laminin-like extracellular matrix. The patent has 3 independent claims all covering essentially the same process. The first one covers induction of growth and proliferation of "mammalian pancreatic epithelial cells into...
Inventors: Harrison, Leonard C. (St Kilda West, AU); Jiang, Fang-Xu (North Melbourne, AU); Stanley, Edouard Guy (Ascot Vale, AU); Gonez, Leonel Jorge (Chadstone, AU)
Assignee: The Walter and Eliza Hall Institute of Medical Research (Victoria, AU)
Date of First Priority Issue: Friday February 18th, 2000
Method for increasing hematopoietic progenitor cells by stem cell factor
Patent Number: 6967029This patent has 2 independent claims both covering the use of stem cell factor for stimulation of hematopoiesis. The first independent claim covers its use in vivo, whereas the second covers its use ex vivo.
Inventors: Zsebo, Krisztina M. (Thousand Oaks, CA); Bosselman, Robert A. (Thousand Oaks, CA); Suggs, Sidney V. (Newbury Parks, CA); Martin, Francis H. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Monday October 16th, 1989
Production of pancreatic islet cells and delivery of insulin
Patent Number: 6967019This patent teaches ways of making gastrointestinal organ cells and pancreatic cells express insulin in vitro, conceptually for introduction in vivo. The patent essentially teaches that introduction of a neuroendocrine class B basic helix-loop-helix (bHLH) transcription factor gene or the neurogenin3 (Ngn3) gene into gastrointestinal organ cells or pancreatic cells, respectively, endows ability...
Inventor: German, Michael S. (Daly City, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Friday June 4th, 1999
Methods of controlling proliferation and differentiation of stem and progenitor cells
Patent Number: 6962698This patent essentially teaches that reducing the copper content in a hematopoietic culture increases efficiency of the culture. The patent has 2 independent claims, the first covering "A method of transplanting expanded undifferentiated hematopoietic cells " and the second covering "A method of adoptive immunotherapy ". The idea that reducing copper content expands ability of...
Inventor:
Assignee: Gamida Cell Ltd. (Jerusalem, IL)
Hadasit Medical Research Services and Development, Ltd. (Jerusalem, IL)
Assignee: Peled, Tony (Mevaseret Zion, IL); Fibach, Eitan (Mevaseret Zion, IL); Treves, Avi (Mevaseret Zion, IL)
Date of First Priority Issue: Tuesday February 17th, 1998
In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients
Patent Number: 6960473This patent teaches how to generate large quantities of erythroid cells in vitro. This is useful for nuclear disasters or situations where large quantities of red blood cells are needed for transfusion purposes. This is a very interesting invention since it uses as the starting population blood cells and not bone marrow. The invention has 1 independent claim covering the method of generating...
Inventors: Migliaccio, Giovanni (Rome, IT); Franco, Anna Rita (Rome, IT)
Assignee: Istituto Superiore di Sanita (Rome, IT)
Date of First Priority Issue: Saturday February 26th, 2005
Method for isolating cells expressing flk-2
Patent Number: 6960446fetal liver kinase 2 (flk-2) is expressed on numerous types of stem cells. This patent covers isolation of cells expressing this marker using either a monoclonal or polyclonal antibody. The patent has 1 independent claim which essentially covers the subject matter previously mentioned. The importance of flk-2 on hematopoietic stem cells was published by the author (Matthews W, et al. A receptor...
Inventor: Lemischka, Ihor R. (Princeton, NJ)
Assignee: The Trustees of Princeton University (Princeton, NJ)
Date of First Priority Issue: Monday February 4th, 1991
Process for producing a vascularized bioartificial tissue and an experimental reactor for carrying out the process
Patent Number: 6960427At face value this patent seems to be extremely broad. The issued claims, which have one independent claim, cover pretty much any type of vascularized bioengineered tissue. The claim is not restricted to type of tissue or method of generating the tissue. It covers the introduction of at least one blood vessel into either a tissue or a matrix which has cells in it, growing of the tissue in...
Inventors: Haverich, Axel (Isernhagen, DE); Kofidis, Theo (Hannover, DE)
Assignee: Artiss GmbH (Hannover, DE)
Date of First Priority Issue: Monday April 3rd, 2000
Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
Patent Number: 6960351One of the main drawbacks of stem cell therapy, or any cell therapy for that matter is that it is important to avoid the issue of immunological rejection. This is why numerous scientists are using autologous stem cells. Unfortunately, there is no such thing as autologous embryonic stem cells. Additionally, the ability to use allogeneic stem cells without rejection would allow for the widespread...
Inventors: Dionne, Keith E. (Rehoboth, MA); Emerich, Dwaine F. (Providence, RI); Hoffman, Diane (Cambridge, MA); Sanberg, Paul R. (Spring Hill, FL); Christenson, Lisa (New Haven, CT); Hegre, Orion D. (Green Valley, AZ); Scharp, David W. (St. Louis, MO); Lacy, Paul E
Assignee: Brown University Research Foundation (Providence, RI)
Date of First Priority Issue: Thursday April 25th, 1991